Danaher (NYSE:DHR) PT Raised to $310.00

Danaher (NYSE:DHR) had its price objective boosted by KeyCorp from $290.00 to $310.00 in a report released on Wednesday morning, Benzinga reports. The brokerage currently has an overweight rating on the conglomerate’s stock.

Several other equities analysts have also commented on the company. Evercore ISI increased their target price on Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Bank of America increased their target price on Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Barclays dropped their target price on Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a report on Wednesday. Wells Fargo & Company assumed coverage on Danaher in a report on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 target price on the stock. Finally, Leerink Partners increased their target price on Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Seven equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $287.28.

Danaher Stock Down 2.0 %

Danaher stock opened at $256.00 on Wednesday. Danaher has a twelve month low of $182.09 and a twelve month high of $281.70. The stock’s fifty day simple moving average is $270.43 and its 200-day simple moving average is $260.43. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $189.62 billion, a P/E ratio of 43.39, a P/E/G ratio of 4.49 and a beta of 0.83.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same quarter in the prior year, the company earned $2.02 earnings per share. The company’s revenue was up 3.1% on a year-over-year basis. As a group, equities analysts expect that Danaher will post 7.59 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.42%. The ex-dividend date is Friday, September 27th. Danaher’s dividend payout ratio is currently 18.31%.

Insider Buying and Selling

In related news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the transaction, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. In related news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the transaction, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Rainer Blair sold 9,007 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the transaction, the chief executive officer now directly owns 97,983 shares in the company, valued at approximately $27,435,240. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 30,059 shares of company stock valued at $8,400,897 over the last quarter. 11.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Danaher

A number of hedge funds have recently added to or reduced their stakes in DHR. Tsfg LLC lifted its position in Danaher by 733.3% in the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 88 shares during the period. CarsonAllaria Wealth Management Ltd. acquired a new stake in Danaher in the second quarter valued at about $25,000. nVerses Capital LLC acquired a new stake in shares of Danaher during the 2nd quarter valued at approximately $25,000. Redmont Wealth Advisors LLC acquired a new stake in shares of Danaher during the 1st quarter valued at approximately $30,000. Finally, MFA Wealth Advisors LLC acquired a new stake in shares of Danaher during the 2nd quarter valued at approximately $51,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.